Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:14
  • preuzimanja u poslednjih 30 dana:6
članak: 4 od 10  
Back povratak na rezultate
Vojnosanitetski pregled
2017, vol. 74, br. 10, str. 921-926
jezik rada: engleski
vrsta rada: izvorni naučni članak
doi:10.2298/VSP150723264D
Creative Commons License 4.0
Faktori rizika od diskinezija uzrokovanih levodopom kod obolelih od Parkinsonove bolesti
aRailway Health Care Institute, Belgrade
bClinical Center of Serbia, Neurology Clinic, Belgrade
cUniverzitet u Beogradu, Medicinski fakultet, Institut za epidemiologiju

e-adresa: marinasvetel@gmail.com

Projekat

Motorni i nemotorni simptomi parkinsonizma: kliničke, morfološke i molekularno-genetičke korelacije (MPNTR - 175090)

Sažetak

Uvod/Cilj. Levodopa, prekursor dopamine pretstavlja supstitucionu terapiju Parkinsonove bolesti. Dugotrajna upotreba levodopa uzrokuje fluktacije motornog odgovora i pojavu neželjenih pokreta ili diskineziju. Cilj rada bio je procena značaja faktora rizika od razvoja diskinezija uzrokovanih levodopom kod obolelih od Parkinskonove bolesti (PB). Metode. Istraživanje je obuhvatilo 177 bolesnika sa PB, regrutovanih na Neurološkoj klinici Kliničkog centra Srbije (Beograd), čije lečenje je trajalo duže od šest meseci. Za ispitivanje obolelih korišćene su standardizovane skale za kvantifikovanje PB, ali i detaljni posebno konstruisani upitnik za ovu studiju sa demografskim i kliničkim podatcima. Rezultati. Bolesnici sa diskinezijama (n = 50) bili su mlađi na početku bolesti i imali su duže trajanje bolesti. Takođe, oboleli sa diskinezijama imali su veće skorove na Unified Parkinson's Disease Rating Scale (UPDRS), učestalije motorne komplikacije - fluktuacije terapijskog odgovora (bilo u formi skraćenja trajanja pojedinačnih doza ('wearing off') ili motornih blokova hoda ('freezing') i češće su ispoljavali medikamentoznu psihozu. Oni su bili i na statistički višim dozama levodope, ali i višoj ekvivalentnoj dozi levodope, pri čemu je njihovo lečenje trajalo značajno duže. Multivarijantna analiza pokazala je da su nezavisni prediktori pojave diskinezija u grupi bolesnika sa PB bili: dužina bolesti preko 10 godina [relativni rizik (RR = 2.90, 95% interval poverenja (IP) 1.19-7.10; p = 0.019), dužina terapije više od 94 meseci (RR = 3.21, 95%IP 1.05-9.87; p = 0.041), dnevna doza levodope u trenutku ispitivanja veća od 537 mg (RR = 3.62, 95%IP 1.57-8.35; p = 0.002). Zaključak. Potvrđen je značaj poznatih faktora rizika od razvoja diskinezija u odmakloj fazi Parkinsonove bolesti.

Ključne reči

Reference

Ahlskog, J. E., Muenter, M.D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders, 16(3): 448-458
Aviles-Olmos, I., Martinez-Fernandez, R., Foltynie, T. (2010) L-dopainduced dyskinesias in Parkinson's disease. Eur Neurol J, 2(2); 91-100
Brooks, D.J., Sturtz, F.G., Latour, P., Mocquard, Y., Cruz, S., Fenoll, B., i dr. (1997) Motor disturbance and brain functional imaging in Parkinson's disease. Eur Neurol, 38 Suppl 2(1): 26-32
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., Durif, F. (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorders, 20(2): 224-230
Cotzias, G.C., Papavasiliou, P.S., Gellene, R. (1969) Modification of Parkinsonism - Chronic Treatment with L-Dopa. New England Journal of Medicine, 280(7): 337-345
Encarnacion, E.V., Hauser, R.A. (2008) Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments. European Neurology, 60(2): 57-66
Fahn, S., Elton, R.L., UPDRS Development Committee (1987) The unified Parkinson's disease rating scale. u: Fahn S, Marsden CD, Calne DB, Goldestein M [ur.] Recent Developments in Parkinson s Disease, Florham Park, NJ: Macmillan Healthcare Information, p. 153-163
Fahn, S. (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease?. Journal of Neurology, 252(S4): iv37-iv42
Folstein, M.F., Folstein, S.E., McHugh, P.R. (1975) 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12(3): 189-98
Foltynie, T., Cheeran, B., Williams-Gray, C.H., Edwards, M.J., Schneider, S.A., Weinberger, D., Rothwell, J.C., Barker, R.A., Bhatia, K.P. (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 80(2): 141-144
Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., Dorflinger, E. E. (1994) Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment. Movement Disorders, 9(4): 390-394
Guy, W.A. (1976) Abnormal Involuntary Movement Scale (AIMS). u: Guy W.A. [ur.] ECDEU Assessment Manual for Psychopharmacology, Washington, DC: US Department of Health Education and Welfare, p. 534-7
Hamilton, M. (1960) A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry, 23: 56-62
Hamilton, M. (1959) The assessment of anxiety states by rating. Br J Med Psychol, 32(1): 50-5
Hely, M.A., Morris, J.G.L., Reid, W.G.J., Trafficante, R. (2005) Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Movement Disorders, 20(2): 190-199
Hoehn, M.M., Yahr, M.D. (1967) Parkinsonism: Onset, progression and mortality. Neurology, 17(5): 427-42
Kostic, V., Przedborski, S., Flaster, E., Sternic, N. (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology, 41(2, Part 1): 202-202
Kostić, V.S., Marinković, J.M., Svetel, M.V., Stefanova, E.D., Przedborski, S. (2002) The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. European Journal of Neurology, vol. 9, br. 1, str. 9-14
Kostić, V.S. (2009) Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. Parkinsonism & Related Disorders, 15: S71-S75
Kuoppamäki, M., Al-Barghouthy, G., Jackson, M. J., Smith, L. A., Quinn, N., Jenner, P. (2007) L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. Journal of Neural Transmission, 114(9): 1147-1153
Macleod, A.D., Counsell, C.E., Ives, N., Stowe, R. (2005) Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev, 3, CD004898
Marras, C., Tanner, C. M. (2004) Epidemiology of Parkinson's disease. u: Watts R.L.; Koller W.C. [ur.] Movement Disorders: Neurologic Principles & Practice, New York: McGraw-Hill, 177-195, 2nd ed
Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J., Lang, A. E. (2002) Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 58(1): 11-17
Olanow, C. W., Schapira, A.H.V., Rascol, O. (2000) Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences, 23: S117-S126
Olanow, W.C., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Bonucelli, U., i dr. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord, 19(9); 997-1005
Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol, 39(1); 37-45
Parkinson Study Group - CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol, 66(5); 563-70
Rajput, A.H., Fenton, M.E., Birdi, S., Macaulay, R., George, D., Rozdilsky, B., Ang, L.C., Senthilselvan, A., Hornykiewicz, O. (2002) Clinical-Pathological study of levodopa complications. Movement Disorders, 17(2): 289-296
Schrag, A., Quinn, N. (2000) Dyskinesias and motor fluctuations in Parkinson's disease. Brain, 123(11): 2297-2305
Schwab, R.S., England, A. (1969) Projection technique for evaluating surgery in Parkinson's disease. u: Gillingham F.; Donaldson I. [ur.] Third symposium on surgery in Parkinson's disease, Edinburg: Livingstone, 152-157
Seppi, K., Weintraub, D., Coelho, M., Perez-Lloret, S., Fox, S.H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C.G., Sampaio, C. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders, 26(S3): S42-S80
Smith, L.A., Jackson, M.J., Hansard, M.J., Maratos, E., Jenner, P. (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure. Movement Disorders, 18(5): 487-495
Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R., Clarke, C.E. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders, 25(15): 2649-2653
van Gerpen, J.A., Kumar, N., Bower, J.H., Weigand, S., Ahlskog, J. E. (2006) Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990. Archives of Neurology, 63(2): 205
Ward, C.D., Gibb, W.R. (1990) Research Diagnostic Criteria for Parkinson's Disease. Adv Neurol, 53: 245-9
Wickremaratchi, M.M., Knipe, M. D.W., Sastry, B.S. D., Morgan, E., Jones, A., Salmon, R., Weiser, R., Moran, M., Davies, D., Ebenezer, L., Raha, S., Robertson, N.P., Butler, C.C., Ben-Sh (2011) The motor phenotype of Parkinson's disease in relation to age at onset. Movement Disorders, 26(3): 457-463
Zappia, M., Annesi, G., Nicoletti, G., Arabia, G., Annesi, F., Messina, D., Pugliese, P., Spadafora, P., Tarantino, P., Carrideo, S., Civitelli, D., de Marco, E.V., Cirò-Candiano, I. (2005) Sex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease. Archives of Neurology, 62(4): 601